Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
NCT ID: NCT00765830
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
349 participants
INTERVENTIONAL
2008-09-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
NCT00567047
Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients
NCT00818571
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
NCT01064414
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
NCT01487109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
50mg qd vildagliptin
vildagliptin
50mg qd
2
Placebo
Placebo
qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vildagliptin
50mg qd
Placebo
qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica de Fracturas y Ortopedia
Buenos Aires, , Argentina
Hospital Teodoro Alvarez
Buenos Aires, , Argentina
Instituto de Investigaciones Clinicas de Mar del Plata
Buenos Aires, , Argentina
Instituto Medico Especializado IME
Buenos Aires, , Argentina
Hospital Juan Ramon Vidal
Corrientes, , Argentina
Clinica Reina Fabiola
Córdoba, , Argentina
Hospital Zenon J. Santillan
San Miguel de Tucumán, , Argentina
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Heidelberg Repatriation Hospital
Heidelberg Heights, , Australia
SA Endocrine Clinical Research
Keswick, , Australia
Keogh Medical Research Institute
Nedlands Perth, , Australia
St Vincent's Hospital (Melb)
Victoria, , Australia
ERS Endocrine Research Society
Vancouver, British Columbia, Canada
Health Sciences Centre - Diabetes Research Group
Winnipeg, Manitoba, Canada
Co Medica Research Network Inc.
Courtice, Ontario, Canada
Ultra Med Inc.
Pointe-Claire, Quebec, Canada
Centre de Recherche de Laval
Laval, , Canada
Private Office (Gottesman)
Ontario, , Canada
Hopital Maisonneuve-Rosemont
Québec, , Canada
Health Sciences Centre - Diabetes Research Group
Winnipeg, , Canada
Clínica Vía San Juan
Cartago, , Costa Rica
Clínica de Endocrinología y Diabetes
San José, , Costa Rica
Clínica San Agustín
San José, , Costa Rica
Hospital Clínica Bíblica
San José, , Costa Rica
Satakunnan Keskussairaala
Pori, , Finland
Mediwest Research Center
Seinäjoki, , Finland
Tampereen lääkärikeskus Oy, Koskiklinikka
Tampere, , Finland
Cabinet du Dr Arnou
Angers, , France
Cabinet du Dr Giraud Philippe
Angers, , France
Hôpital Docteur Duchenne
Boulogne-sur-Mer, , France
Hopital Albert Michallon
Grenoble, , France
Cabinet médical
Laval, , France
Hopital Dupuytren
Limoges, , France
Hopital Edouard Herriot
Lyon, , France
Zentralklinikum Augsburg
Augsburg, , Germany
Praxis Dr. Maxeiner
Bad Kreuznach, , Germany
Universitaetsklinik Charitè
Berlin, , Germany
Praxis Dr. Fischer
Darmstadt, , Germany
Praxis Dr. Merker
Dormagen, , Germany
Univ.-Klinikum Erlangen
Erlangen, , Germany
Kardiol. Gemeinschaftspraxis PD Dr. Winkelmann
Frankfurt, , Germany
Universitätsklinikum Frankfurt
Frankfurt, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Friedrich Schiller Universitaet Jena
Jena, , Germany
CRS Clinical Research Services Gmbh
Kiel, , Germany
I. Medizinische Univ.-Klinik
Kiel, , Germany
Praxis Dr. Hennig
Meissen, , Germany
Praxis Dr. Grimm
München, , Germany
Univ.-Klinikum München, Campus Innenstadt
München, , Germany
Praxis Dr. Schoell
Nuremberg, , Germany
Forschungszentrum Ruhr, KliFoCenter GmbH
Witten, , Germany
Universitaetsklinik im Luitpold-Krankenhaus
Würzburg, , Germany
Gujarat Endocrine Centre
Ahmedabad, , India
M V Hospital for Diabetes and Diabetic Research Center
Chennai, , India
Coimbatore Diabetes Foundation
Coimbatore, , India
S.R. Kalla Memorial Gastro & General Hospital
Jaipur, , India
Meenakshi Mission Hospital & Research Centre
Madurai, , India
Diabetes Clinic & Research Centre
Nagpur, , India
Storoklinikken
Oslo, , Norway
St. Olavs Hospital, Endokrinologisk seksjon
Trondheim, , Norway
City Clinical Hospital #6
Chelyabinsk, , Russia
City Clinical Hospital #1
Moscow, , Russia
City Clinical Hospital No.11
Moscow, , Russia
MSU of Medicine and Dentistry on the base of CityHospital 23
Moscow, , Russia
MSUMD on the base of City Clinical Hospital #67
Moscow, , Russia
City polyclinic # 17, City Diabetic Centre #3
Saint Petersburg, , Russia
Krestovsky Island Medical Institute
Saint Petersburg, , Russia
Saint- Petersburg State Mtchnikov's Medical Academy
Saint Petersburg, , Russia
Saint-Petersburg State Pavlov's Medical University
Saint Petersburg, , Russia
Site Management Organisation of Clinical Trials Centers
Smolensk, , Russia
Tyumen State Medicine Academy
Tyumen, , Russia
Clinica Mediterranea de Neurociencias
Alicante, , Spain
Hospital de la Ribera
Alzira, , Spain
Hospital Clinic I Provincial de Barcelona
Barcelona, , Spain
Centro de Salud Begonte
Begonte, , Spain
Hospital San Pedro de Alcantara
Cáceres, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital General de Jerez de La Frontera
Jerez de la Frontera, , Spain
Ciutat Sanitaria I Universitaria de Bellvitge
L'Hospitalet de Llobregat, , Spain
Complejo Universitario de San Carlos
Madrid, , Spain
Hospital de Merida
Mérida, , Spain
Hospital Son Dureta
Palma de Mallorca, , Spain
Consorci Hospitalari Parc Tauli
Sabadell, , Spain
Hospital Clinico Universitario Santiago de Compostela
Santiago de Compostela, , Spain
Eap El Remei - Vic
Vic, , Spain
ME3PLUS Clinical Trials
Gothenburg, , Sweden
Njurmedicin, Sahlgrenska Univ.sjukhuset
Gothenburg, , Sweden
Metabolmottagningen, Lasarettet, Kristianstad
Kristianstad, , Sweden
VO Endokrinologi/Diabetologi Universitetssjukhuset
Lund, , Sweden
Ladulaas Kliniska Studier
Skene, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CLAF237A23137E1 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLAF237A23137E1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.